Recombinant DNA technology is all vogue these days. It is subject of intense media and investor interest. It has lured tens of millions of dollars from industry to support academic research, spawned a seemingly endless succession of symposia examining every nuance of technology, and fostered development of a hundred recombinant DNA companies in a dozen countries. But those who are bullish on this new technology had best be prepared to be patient, at least for short term; most of prognostications made about this new area are almost surely overly optimistic. Even authoritative and useful report by Congress' Office of Technology Assessment, Impacts of Applied Genetics , recently hyperbolized that the immediate direct economic impact of using genetic manipulation in [pharmaceutical] industry, measured as sales, can be estimated in billions of dollars, with indirect impacts... reaching several times that value. This
Read full abstract